Investigational Drug Details
| Drug ID: | D179 |
| Drug Name: | Icosabutate |
| Synonyms: | Icosabutate |
| Type: | Chemical drug |
| DrugBank ID: | DB12990 |
| DrugBank Description: | Icosabutate is under investigation in clinical trial NCT02373176 ( Icosabutate -A Phase I Absorption, Metabolism and Excretion Study). |
| PubChem ID: | 78210211 |
| CasNo: | 1253909-57-7 |
| Repositioning for NAFLD: | No |
| SMILES: | C(OCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)(C(=O)O)CC |
| Structure: |
|
| InChiKey: | VOGXDRFFBBLZBT-AAQCHOMXSA-N |
| Molecular Weight: | 374.565 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (NCT04052516) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0222 | NCT04052516 | Phase 2 | Active, not recruiting | No Results Available | July 17, 2019 | December 20, 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00971 | 34915054 | J Hepatol | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | Details |
| A06522 | 32841505 | Liver Int | Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. | Details |
| A30665 | 32025605 | Hepatol Commun | Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. | Details |